The safety of calcium channel blockers in human pregnancy: A prospective, multicenter cohort study


      OBJECTIVE: Our purpose was to examine the potential teratogenicity of calcium channel blockers. STUDY DESIGN: Six teratogen information services prospectively collected and followed up 78 women with first-trimester exposure to calcium channel blockers. Pregnancy outcome was compared (by paired t test or χ2 analysis) with that of a control group matched for maternal age and smoking. RESULTS: There was no increase in major malformations (2/66 = 3.0% [calcium channel blockers] vs 0% [nonteratogenic controls], p = 0.27); a fivefold increase was ruled out (baseline 2%, α = 0.05, β = 0.20). The defects reported were attributable to maternal diabetes or coingestion of teratogens. The increase in preterm delivery (28% [calcium channel blockers] vs 9% [nonteratogenic controls], p = 0.003), attributed to maternal disease by stepwise regression, was the most important factor responsible for the observed decrease in birth weight (mean -334 gm vs nonteratogenic controls, p = 0.08). CONCLUSION: This study suggests that calcium channel blockers do not represent a major teratogenic risk. (AM J OBSTET GYNECOL 1996;174:823-8.)


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Skrabanek P.
        Smoking and statistical overkill.
        Lancet. 1992; 340: 1208-1209
      1. 2nd ed. Maternal-fetal toxicology: a clinician's guide. : Marcel Dekker, New York1994
        • Ariyuki F.
        Effects of diltiazem hydrochloride on embryonic development: species differences in susceptibility and stage specificity in mice, rats and rabbits.
        Okajimas Folia Anat Jpn. 1975; 52: 103-107
        • Danielsson BR
        • Reiland S
        • Rundqvist E
        • Danielson M.
        Digital defects induced by vasodilating agents: relationship to reduction in uteroplacental blood flow.
        Teratology. 1989; 40: 351-358
        • Danielsson BR
        • Danielson M
        • Reiland S
        • Rundqvist E
        • Dencker L
        • Regard CG.
        Histological and in vitro studies supporting decreased uteroplacental blood flow as explanation for digital defects after administration of vasodilators.
        Teratology. 1990; 41: 185-193
      2. Felodipine product monograph. West Point, Pennsylvania: Merck Sharp and Dohme.

        • Yoshida T
        • Tadegawa Y
        • Miyago M
        • Hasegawa Y.
        Hyperphalangism induced by Ca-blockers in rat fetuses.
        Teratology. 1989; 40: 668-669
      3. Nifedipine product monograph. : Miles Pharmaceuticals, Elkhart, Indiana1992
        • Lubbe WF.
        Use of diltiazem during pregnancy.
        N Z Med J. 1987; 100: 121
        • Frenkel Y
        • Barkai G
        • Resin L
        • Rath S
        • Mashiach S
        • Battler A.
        Pregnancy after myocardial infarction: are we playing safe?.
        Obstet Gynecol. 1991; 77: 822-825
        • Wilson AG
        • Kirby JD.
        Successful pregnancy in a woman with systemic sclerosis while taking nifedipine.
        Ann Rheum Dis. 1990; 49: 51-52
        • Colina-Chourio JA
        • Godoy N
        • Oliveros-Palacios M
        • Villarroel MN
        • Arocha I.
        Successful pregnancy in a severe hypertensive patient treated with nitrendipine: case report.
        Invest Clin. 1992; 33: 61-67
        • Koren G
        • Bologa M
        • Long D
        • Henderson K
        • Feldman Y
        • Shear N.
        Perception of teratogenic risk by pregnant women exposed to drugs and chemicals in early pregnancy.
        AM J OBSTET GYNECOL. 1989; 160: 1190-1194
        • Marden PM
        • Smith DW
        • McDonald MJ.
        Congenital anomalies in the newborn infant, including minor variations.
        J Pediatr. 1964; 64: 357-371
        • Duminy PC
        • Burger PT.
        Fetal abnormality associated with the use of captopril during pregnancy.
        S Afr Med J. 1981; 805
        • Schardein J.
        Chemically induced birth defects.
        in: : Marcel Dekker, New York1985: 174-175
        • Niesen M
        • Froscher W.
        Finger- and toenail hypoplasia after carbamazepine monotherapy in late pregnancy.
        Neuropediatrics. 1985; 16: 167-168
        • Kirshon B
        • Wasserstrum N
        • Willis R
        • Herman GE
        • McCabe ERB.
        Teratogenic effects of first trimester cyclophosphamide therapy.
        Obstet Gynecol. 1988; 72: 462
        • Jelovsek FR
        • Mattison DR
        • Chen JJ.
        Prediction of risk for human developmental toxicity: how important are animal studies for hazard indentification?.
        Obstet Gynecol. 1989; 74: 624-636
        • Pratt RM.
        Receptor-dependent mechanisms of glucocorticoid and dioxin-induced cleft palate.
        Environ Health Perspect. 1985; 61: 35-40
        • Walker JJ
        • Mathers A
        • Bjornsson S
        • Cameron AD
        • Fairlie FM.
        The effect of acute and chronic antihypertensive therapy on maternal and fetoplacental Doppler velocimetry.
        Eur J Obstet Gynecol Reprod Biol. 1992; 43: 193-199
        • Hennessy A
        • Gillin A
        • Horvath J.
        Cardiovascular research in pregnancy: the role of animal models.
        Hypertens Pregnancy. 1993; 12: 413-437
      4. Prevention of low birth weight in Canada: literature review and strategies. : Canadian Institute of Child Health, Ottawa1992
        • Sibai BM
        • Barton JR
        • Akl S
        • Sarinoglu C
        • Mercer BM.
        A randomized prospective comparison of nifedipine and bed rest versus bed rest alone, in the management of preeclampsia remote from term.
        AM J OBSTET GYNECOL. 1992; 167: 879-884